BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05904470 (Bemnifosbuvir Ruzasvir in Chronic Hepatitis C Virus): BVCT ex-ante prediction vs. reported outcome

On 1 Dec 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 5 Jun 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially TBD.

Clinical Trial

NCTID
NCT05904470
Drug Name
Bemnifosbuvir Ruzasvir
Drug MoA
viral RNA polymerase inhibitor
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Infections
Indication
Chronic Hepatitis C Virus
Human Patients
275
Sponsor
Atea Pharmaceuticals
Phase
Phase 2

Prediction of , index 1198

Prospective Prediction
Prediction Index
1198
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
187 days in advance
Readout Data Interpretation
achieved 97% SVR12
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially TBD
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Open-label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
Phase
Phase 2
Status
Completed
Enrollment
275
Lead sponsor
Atea Pharmaceuticals, Inc.
Conditions
Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C; Hepatic Cirrhosis; HCV
Interventions
DRUG: Bemnifosbuvir; DRUG: Ruzasvir
Design
Single group · None
Primary purpose
Treatment
Start
2023-05-30
Primary completion
2024-12-09
Completion
2025-01-28
Results first posted
2025-10-21
Primary outcomes
  • Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12) (Day 1 through 12 weeks after end of treatment)

NCT05904470 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials